CN106309414A - Application of protocatechuic aldehyde in drug for treating acute kidney injury and prepared drug for treating acute kidney injury - Google Patents
Application of protocatechuic aldehyde in drug for treating acute kidney injury and prepared drug for treating acute kidney injury Download PDFInfo
- Publication number
- CN106309414A CN106309414A CN201610711489.2A CN201610711489A CN106309414A CN 106309414 A CN106309414 A CN 106309414A CN 201610711489 A CN201610711489 A CN 201610711489A CN 106309414 A CN106309414 A CN 106309414A
- Authority
- CN
- China
- Prior art keywords
- protocatechualdehyde
- cisplatin
- group
- kidney
- kidney injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a preventive and therapeutic effect of protocatechuic aldehyde on an acute kidney injury and belongs to the pharmaceutical industry field. The invention relates to a new medical application of protocatechuic aldehyde and particularly relates to an inflammatory response caused by effectively reducing the acute kidney injury with protocatechuic aldehyde and further plays a role to kidney protection.
Description
Technical field
The invention belongs to pharmaceutical industries field, relate to the medical usage of protocatechualdehyde, be specifically related to protocatechualdehyde in treatment
Purposes in acute injury of kidney medicine and the treatment acute injury of kidney medicine of preparation thereof.
Background technology
Acute injury of kidney (Acute Kidney Injury, AKI) is clinical common critical illness, may result in kidney the completeest
Full reparation, lasting chronic inflammatory disease and progressivity fibrosis, be to cause subsequent chronic nephropathy, renal failure and inpatient dead
Major reason.AKI there is no any effective remedy measures up to now, and therefore, searching can alleviate tissue injury, promote to repair
Protection renal medicine multiple, that prevent chronic fibrosis from occurring is significant.
Protocatechualdehyde (Protocatechuic Aldehyde, PA) often separates from the root of labiate Radix Salviae Miltiorrhizae, obtains
A kind of phenolic acid compound, in Lindsaeaceae plant Folium Stenolomatis leaf, holly plant Folium Ilicis Purpureae also contains.Research in the past
Result shows, protocatechualdehyde has biological activity widely, activating blood circulation to dissipate blood stasis, freeing vessels and nourishing heart.It is usually used in coronary heart disease, uncomfortable in chest, angina pectoris
Deng treatment, but it is used as the medicine for the treatment of acute injury of kidney, and pharmacotoxicological effect is not yet reported.
Summary of the invention
It is an object of the invention to provide the medicinal usage that protocatechualdehyde is new, be specifically related to protocatechualdehyde in treatment acute kidney
Purposes during damage.
The application in treatment acute injury of kidney medicine of a kind of protocatechualdehyde, the molecular formula of described protocatechualdehyde is C7H6O3,
Its chemical structural formula is as follows:
Treatment acute injury of kidney medicine prepared by described protocatechualdehyde, it is characterised in that: this medicine is by described former youngster
Tea aldehyde and pharmaceutically acceptable adjuvant prepare.
The described treatment acute injury of kidney medicine utilizing protocatechualdehyde to prepare, it is characterised in that its dosage form be injection,
Tablet, pill, capsule, suspending agent or Emulsion.
The invention have the benefit that experimental result confirms that protocatechualdehyde can effectively alleviate acute injury of kidney, protect kidney merit
Can, its mechanism of action reduces inflammatory factor level with protocatechualdehyde and oxidative stress level is relevant, and application prospect is extensive.
Accompanying drawing explanation
Fig. 1 protocatechualdehyde (PA) significantly alleviates the Cisplatin damage to renal cells；
Compare with matched group (NC): * P < 0.05, * * P < 0.01, * * * P < 0.001；Compare with cisplatin stimulation group (Cis):#P
<0.05,##P<0.01,###P<0.001
Such as figure (a): MTT result shows that protocatechualdehyde substantially alleviates the cisplatin growth inhibited effect to HK2 cell；Figure (b):
Western Blot and semi-quantitative analysis result display protocatechualdehyde can suppress the Kidney injury molecule (KIM-1) that cisplatin stimulates
Protein expression level.
Fig. 2 protocatechualdehyde (PA) significantly alleviates the renal cells inflammatory factor level of Cisplatin induction；With right
Compare according to group (NC): * P < 0.05, * * P < 0.01, * * * P < 0.001；Compare with cisplatin stimulation group (Cis):#P<0.05,##P<
0.01,###P<0.001.Figure (c): Real-time PCR result shows that protocatechualdehyde can substantially reduce in cisplatin induction HK2 cell
The mRNA level in-site of MCP-1；Figure (d): protocatechualdehyde can substantially reduce the mRNA level in-site of IL-8 in cisplatin induction HK2 cell.
Fig. 3 protocatechualdehyde (PA) significantly alleviates the renal cells oxidative stress level of Cisplatin induction；
Compare with matched group (NC): * P < 0.05, * * P < 0.01, * * * P < 0.001；Compare with cisplatin stimulation group (Cis): #P
<0.05,##P<0.01,###P<0.001。
Figure (e): protocatechualdehyde can substantially reduce reactive oxygen species in cisplatin induction HK2 cell.
Fig. 4 protocatechualdehyde (PA) significantly reduces serum creatinine and the urea nitrogen levels of acute renal injury in mice model, protects kidney
Function；Compare with matched group (NC): * P < 0.05, * * P < 0.01, * * * P < 0.001；Compare with cisplatin stimulation group (Cis): #P <
0.05,##P<0.01,###P<0.001.Figure (f): the protocatechualdehyde of variable concentrations can reduce chmice acute kidney to some extent to be damaged
The content of serum creatinine in wound model；Figure (g): protocatechualdehyde reduces the content of blood urea nitrogen in acute renal injury in mice model.
Fig. 5 protocatechualdehyde (PA) significantly reduces inflammatory factor level in acute renal injury in mice model；
Compare with matched group (NC): * P < 0.05, * * P < 0.01, * * * P < 0.001；Compare with cisplatin stimulation group (Cis): #P
<0.05,##P<0.01,###P<0.001.Figure (h) and figure (i): protocatechualdehyde substantially reduces in acute renal injury in mice model
IL-6mRNA, MCP-1mRNA level；Figure (j) Real-time PCR result display protocatechualdehyde can substantially reduce chmice acute kidney
TNF-α mRNA level in-site in damage model.
Fig. 6: protocatechualdehyde (PA) significantly reduces oxidative stress level in acute renal injury in mice model；
Compare with matched group (NC): * P < 0.05, * * P < 0.01, * * * P < 0.001；Compare with cisplatin stimulation group (Cis): #P
< 0.05, ##P < 0.01, ###P < 0.001, scheme (k): protocatechualdehyde substantially increases reduction in cisplatin mediated acute renal injury model
Type glutathion (Reduced glutathione, GSH) content；Figure (l): protocatechualdehyde substantially reduces acute renal injury in mice
Malonaldehyde (Malondialdehyde, MDA) content in model.
Detailed description of the invention
Case study on implementation 1: protocatechualdehyde protective effect to cisplatin induced injury of proximal cells in vitro；
Mtt assay: be inoculated in 96 orifice plates by people's renal cells (HK2) cell, inoculum density is about 4000 carefully
Born of the same parents/hole.Cultivating 24h, after using serum-free medium instead hungry 12 hours, packet adds cisplatin and protocatechualdehyde, is respectively normal
Group (NC), model group (Cisplatin 20 μMs), protocatechualdehyde low dosage (20 μMs of+PA of Cisplatin 0.25 μM), middle dosage
(20 μMs of+PA of Cisplatin 0.5 μM), high dose group (20 μMs of+PA of Cisplatin 1 μM), continue to cultivate 24h.Cultivate knot
After bundle, every hole adds 5g L-1MTT solution 20 μ L, continue cultivate 4h.Sucking culture medium, every hole adds the DMSO of 150 μ L, shakes
Swing, mixing.At 492nm, measure each hole OD value by microplate reader, record result.Right with cell survival rate (Cell viability)
Plotted versus dosage.Result calculates: cell survival rate=(test group cell OD value-blank group cell OD value)/(cellular control unit OD
Value-blank group cell OD value) × 100%.
Western Blot: be inoculated in 6 orifice plates by the HK2 cell of exponential phase, is respectively divided into normal group (NC), mould
Type group (Cisplatin 20 μMs) and protocatechualdehyde low dosage (20 μMs of+PA of Cisplatin 0.25 μM), middle dosage
(20 μMs of+PA of Cisplatin 0.5 μM), high dose group (20 μMs of+PA of Cisplatin 1 μM), often group repeats 3-4 experiment.
Inoculum density is about 1.0 × 105Individual cell/ml, adds and stimulates and after medicine, continues to cultivate 24 hours.PBS washes three times, collects
Cell, extracts total protein, detects the protein expression of Kidney injury molecule KIM-1 by Western Blot method and carries out sxemiquantitative
Analyze.
Scheme (a) in experimental result such as Fig. 1, i.e. MTT result shows, the HK2 cell that cisplatin stimulates is through basic, normal, high concentration
Protocatechualdehyde process after, the relative survival rate value of this cell is increased to 84%, 76% and respectively from the 47% of cisplatin stimulation group
88%, survival rate increase about 1.8 times.Illustrate that the renal cells that cisplatin stimulates is had by protocatechualdehyde and preferably protect work
With.
Figure (b) i.e. Western Blot and semi-quantitative analysis result shows, the HK2 cell that cisplatin stimulates is through protocatechualdehyde
After process, the protein expression level of Kidney injury molecule KIM-1 is substantially suppressed, it was demonstrated that cisplatin is caused kidney little by protocatechualdehyde
The protective effect of pipe epithelial damage.
Case study on implementation 2: the protocatechualdehyde inhibitory action to external cisplatin induction inflammatory factor；
HK2 cell is inoculated in 12 orifice plates, is respectively divided into normal group (NC), model group (Cisplatin20 μM) and former
Catechu aldehyde low dosage (20 μMs of+PA of Cisplatin 0.25 μM), middle dosage (20 μMs of+PA of Cisplatin 0.5 μM), high dose
Group (20 μMs of+PA of Cisplatin 1 μM), often group repeats 3-4 experiment.Inoculum density is about 0.5 × 105Individual cells/well, incubates
Educate 24 hours and be separately added into stimulation and medicine with serum-free medium after hungry 12 hours.Continue to cultivate 24 hours.PBS washes three
Time, collect cell, propose RNA, reverse transcription, amplification.
Real time PCR result is as schemed (c) in Fig. 2, and cisplatin substantially induces MCP-1mRNA water in renal cells
Flat rising, and protocatechualdehyde process group MCP-1mRNA is expressed and is substantially suppressed, figure (d) result display renal cells
Processing through protocatechualdehyde after being stimulated by cisplatin, its IL-8mRNA expresses and is decreased obviously, and prompting protocatechualdehyde can significantly inhibit suitable
The inflammatory reaction of platinum induction.
Case study on implementation 3: the protocatechualdehyde inhibitory action to external cisplatin induction oxidative stress；
The HK2 cell of exponential phase is inoculated in 6 orifice plates, is respectively divided into normal group (NC), model group
(Cisplatin 20 μMs) and protocatechualdehyde group (20 μMs of+PA of Cisplatin 0.5 μM), often group repeats 3-4 experiment.Inoculation
Density is about 1.0 × 105Individual cell/ml, adds and stimulates and after medicine, continues to cultivate 24 hours, uses the active oxygen in the green skies
Test kit (S003) detection active o content, reacts oxidative stress level.DCFH-is diluted according to 1:1000 serum-free medium
DA, makes final concentration of 10 micromoles per liter, removes cell culture fluid, adds 1 milliliter of DCFH-DA diluted, 37 degrees Celsius of cells
Incubator is hatched 20 minutes, with serum-free cell culture medium washed cell three times, is introduced into intracellular DCFH-with abundant removal
DA, uses 488nm excitation wavelength, and 525nm launches wavelength, and before and after in real time or stimulating by time point detection, fluorescence is strong and weak and takes pictures.
Scheming (e) in result such as Fig. 3, cisplatin substantially induces the rising of oxidative stress level in renal cells, and former
Catechu aldehyde process group active oxygen produces and reduces, and oxidative stress level reduces.
Case study on implementation 4: protocatechualdehyde is to serum creatinine (Creatinine) in acute injury of kidney model and blood urea nitrogen (BUN)
Impact.
6-8 week old C57BL/6 mice adaptability is raised 1 week, is divided into Normal group (NC), model group (Cisplatin
20mg/kg), protocatechualdehyde low dose group (Cisplatin 20mg/kg+PA 0.45mg/kg), middle dosage group (Cisplatin
20mg/kg+PA 0.9mg/kg), high dose group (Cisplatin 20mg/kg+PA1.8mg/kg), often group 6-10 is only.Mice abdomen
Chamber injection 20mg/kg cisplatin is set up acute injury of kidney model and injects the protocatechualdehyde of basic, normal, high dosage and carry out pharmaceutical intervention, and 3
Collect serum sample and nephridial tissue after it under narcotism, and detect animal mould according to serum creatinine and blood urea nitrogen test kit description
The content (building up Bioengineering Research Institute purchased from Nanjing) of type creatinine in serum and blood urea nitrogen,
Creatinine is tested
Creatinine content (μm ol/L)=[(measure A2-K* and measure A1)-(blank A2-K* blank A1)]/[(standard A2-K* is marked
Quasi-A1)-(blank A2-K* is blank)] * standard concentration (442 μm ol/L)
Note: dilution gfactor K=(sample-adding amount+enzymatic solution A volume)/(sample-adding amount+enzymatic solution A volume+enzymatic solution B volume)=
186/246
Blood urea nitrogen is tested
Urea nitrogen content (mmol/L)=(measuring OD value-blank determination value)/(standard OD value-blank OD value) * standard is dense
Extension rate before degree (10mmol/L) * test sample
Scheming (f) display in experimental result such as Fig. 4, in cisplatin induction model group, serum creatinine content is significantly raised, and renal function is disliked
Changing, and the protocatechualdehyde of variable concentrations effectively reduces model group serum creatinine level, figure (g) result shows the former of variable concentrations equally
Catechu aldehyde effectively reduces model group urea level, is further characterized by protocatechualdehyde and has protection work to renal function during acute injury of kidney
With.
Case study on implementation 5: protocatechualdehyde is to the inhibitory action of inflammation in acute injury of kidney model；
6-8 week old C57BL/6 mice adaptability is raised 1 week, is divided into Normal group (NC), model group (Cisplatin
20mg/kg), protocatechualdehyde low dose group (Cisplatin 20mg/kg+PA 0.45mg/kg), middle dosage group (Cisplatin
20mg/kg+PA 0.9mg/kg), high dose group (Cisplatin 20mg/kg+PA1.8mg/kg), often group 6-10 is only.Mice abdomen
Chamber injection 20mg/kg cisplatin is set up acute injury of kidney model and injects the protocatechualdehyde of basic, normal, high dosage and carry out pharmaceutical intervention, and 3
Collect blood sample and nephridial tissue after it under narcotism, extract tissue RNA, reverse transcription, amplification.
Real-time PCR result is as schemed (h) in Fig. 5, and in acute injury of kidney model, inflammatory factor MCP-1mRNA level shows
Writing and rise, and protocatechualdehyde can obviously reduce inflammatory factor level, improve inflammation, figure i (h) result shows equally, protocatechualdehyde
Can reduce the model group kidney IL-6mRNA high expressed that cisplatin causes, and figure (j) result, protocatechualdehyde can obviously reduce TNF-
α mrna expression, one of this mechanism of action being probably protocatechualdehyde protection acute injury of kidney.
Case study on implementation 6: protocatechualdehyde is to the inhibitory action of oxidative stress level in acute injury of kidney model；
6-8 week old C57BL/6 mice adaptability is raised 1 week, is divided into Normal group (NC), model group (Cisplatin
20mg/kg), protocatechualdehyde low dose group (Cisplatin 20mg/kg+PA 0.45mg/kg), middle dosage group (Cisplatin
20mg/kg+PA 0.9mg/kg), high dose group (Cisplatin 20mg/kg+PA1.8mg/kg), often group 6-10 is only.Mice abdomen
Chamber injection 20mg/kg cisplatin is set up acute injury of kidney model and injects the protocatechualdehyde of basic, normal, high dosage and carry out pharmaceutical intervention, and 3
Blood sample and nephridial tissue is collected under narcotism, according to reduced glutathion (GSH) test kit and malonaldehyde (MDA) after it
Test kit description measures reduced glutathion (GSH) and malonaldehyde (MDA) content, and reaction oxidative stress level (is purchased
Bioengineering Research Institute is built up) from Nanjing.
Reduced glutathion is tested
| Blank well | Gauge orifice | Measure hole | |
| Reagent one (μ l) | 100 | ||
| 20 μm ol/LGSH standard substance (μ l) | 100 | ||
| Supernatant (μ l) | 100 | ||
| Reagent two (μ l) | 100 | 100 | 100 |
| Reagent three (μ l) | 25 | 25 | 25 |
Mixing, static 5 minutes, at 405nm, microplate reader measured each hole absorbance.
GSH content (μm ol/L)=(measuring OD value-blank determination value)/(standard OD value-blank OD value) * standard in serum
Pipe concentration (20 μm ol/L) * Sample pretreatment extension rate (5 times)
Malonaldehyde is tested
| Blank well | Gauge orifice | Measure hole | |
| Dehydrated alcohol (μ l) | 100 | ||
| 10mmol/mL standard substance (μ l) | 100 | ||
| Test sample (μ l) | 100 | ||
| Working solution (μ l) | 1000 | 1000 | 1000 |
Swirl mixing device mixes, and test tube mouth antistaling film tightens, and stings an aperture with syringe needle, 95 DEG C of water-baths (or open with pot
Lid boils) 40 minutes, flowing water cooling after taking-up, then 3500～4000 revs/min, centrifugal 10 minutes, (less than 3000 revs/min from
The heart time needs to extend, and purpose makes the precipitation complete).Taking supernatant, at 532nm, 1cm optical path, distilled water returns to zero, surveys each pipe absorbance
Value.
MDA content (nmol/ml)=(measuring OD value-blank determination value)/(standard OD value-blank OD value) * mark in serum
Extension rate before quasi-product concentration (10nmol/ml)/test sample.
Scheming (k) in experimental result such as Fig. 6, in the model group of cisplatin mediation, reduced glutathion (GSH) content reduces,
Reaction oxidative stress level substantially increases, and meanwhile, protocatechualdehyde administration concentration increases, and glutathione content increases, indirect reaction
Oxidative stress level reduces；In figure (l), the protocatechualdehyde of variable concentrations effectively reduces model group mda content, reduces oxidation
Stress urea level, be further characterized by protocatechualdehyde and renal function during acute injury of kidney had protective effect.
Claims (3)
1. a protocatechualdehyde application in treatment acute injury of kidney medicine, the molecular formula of described protocatechualdehyde is C7H6O3,
Its chemical structural formula is as follows:
2. the treatment acute injury of kidney medicine that a kind utilizes protocatechualdehyde as claimed in claim 1 to prepare, it is characterised in that: institute
State medicine to be prepared by described protocatechualdehyde and pharmaceutically acceptable adjuvant.
The treatment acute injury of kidney medicine utilizing protocatechualdehyde to prepare the most according to claim 2, it is characterised in that: its agent
Type is injection, tablet, pill, capsule, suspending agent or Emulsion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610711489.2A CN106309414A (en) | 2016-08-23 | 2016-08-23 | Application of protocatechuic aldehyde in drug for treating acute kidney injury and prepared drug for treating acute kidney injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610711489.2A CN106309414A (en) | 2016-08-23 | 2016-08-23 | Application of protocatechuic aldehyde in drug for treating acute kidney injury and prepared drug for treating acute kidney injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106309414A true CN106309414A (en) | 2017-01-11 |
Family
ID=57741408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610711489.2A Pending CN106309414A (en) | 2016-08-23 | 2016-08-23 | Application of protocatechuic aldehyde in drug for treating acute kidney injury and prepared drug for treating acute kidney injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106309414A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100998689A (en) * | 2006-01-11 | 2007-07-18 | 胡跃辉 | Traditional Chinese medicine preparation for treating chronic nephritis, kidney failure |
| CN101181255A (en) * | 2006-11-14 | 2008-05-21 | 山东绿叶天然药物研究开发有限公司 | Medication new purpose of protocatechualdehyde |
| CN103417914A (en) * | 2013-07-30 | 2013-12-04 | 黄淮学院 | TCM composition for treatment of acute renal failure |
| CN103417526A (en) * | 2012-05-15 | 2013-12-04 | 上海绿谷制药有限公司 | Application of salvianolate in preparation of kidney protective agent drugs |
-
2016
- 2016-08-23 CN CN201610711489.2A patent/CN106309414A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100998689A (en) * | 2006-01-11 | 2007-07-18 | 胡跃辉 | Traditional Chinese medicine preparation for treating chronic nephritis, kidney failure |
| CN101181255A (en) * | 2006-11-14 | 2008-05-21 | 山东绿叶天然药物研究开发有限公司 | Medication new purpose of protocatechualdehyde |
| CN103417526A (en) * | 2012-05-15 | 2013-12-04 | 上海绿谷制药有限公司 | Application of salvianolate in preparation of kidney protective agent drugs |
| CN103417914A (en) * | 2013-07-30 | 2013-12-04 | 黄淮学院 | TCM composition for treatment of acute renal failure |
Non-Patent Citations (4)
| Title |
|---|
| 李方玲等: "《简明中西医结合肾脏病学》", 31 October 2008 * |
| 赖荣德等: "《危重急症识别与处置》", 30 April 2009 * |
| 迟炘: "《中西医结合儿科常见病手册》", 30 June 2014 * |
| 陈 楠: "急性肾损伤与药物合理使用", 《上海医学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhao et al. | Quercetin protects ethanol-induced hepatocyte pyroptosis via scavenging mitochondrial ROS and promoting PGC-1α-regulated mitochondrial homeostasis in L02 cells | |
| CN109381472A (en) | A kind of glucoside compound is in preparation for treating the application in hepatic fibrosis medicines | |
| CN110025717B (en) | Application of timosaponin enzymatic hydrolysate in preparation of medicines for inhibiting skin superficial fungi | |
| CN102526022A (en) | Application of epigallocatechin-3-gallate in preparation of antitumor drug | |
| CN102526019B (en) | Use of usnic acid and derivatives of usnic acid for preparation of medicaments for treating skin diseases caused by malassezia | |
| Kuete et al. | Toxicological evaluation of the hydroethanol extract of Tabernaemontana crassa (Apocynaceae) stem bark | |
| CN102106914A (en) | Medicament for treating infectious diseases, preparation method and application thereof | |
| CN112353797B (en) | Application of indole-3-acetonitrile in preparation of medicine for treating or preventing influenza virus infection | |
| CN100443080C (en) | Medicinal composition for preventing and treating cancer diseases | |
| Demeekul et al. | A cardiac protection of germinated brown rice during cardiopulmonary bypass surgery and simulated myocardial ischemia | |
| CN103933048A (en) | Applications of ursolic acid derivatives in preparation of drug for preventing and treating tumor metastasis | |
| CN106309414A (en) | Application of protocatechuic aldehyde in drug for treating acute kidney injury and prepared drug for treating acute kidney injury | |
| CN103880826A (en) | Isobenzofuranone compounds as well as preparation method and application thereof | |
| CN103251636B (en) | Medicament for treating Candida infections and diseases caused by Candida, and preparation method thereof | |
| CN103169694A (en) | Application of n-butenyl phthalide in preparing medicine for treating liver injury and improving liver function and pharmaceutical composition | |
| CN103181891A (en) | Andrographolide injection and preparation method thereof | |
| CN109908167B (en) | Application of linarin in preparation of medicine for treating renal ischemia-reperfusion injury by protecting renal tubular epithelial cells | |
| Suedmeyer et al. | Treatment of epidermal cysts associated with Aspergillus fumigatus and Alternaria species in a silky bantam chicken | |
| CN105287488A (en) | Application of wogonin in treating acute kidney injury and medicine prepared by wogonin for treating acute kidney injury | |
| CN112353877A (en) | Application of valerian total alkaloid extract in preparation of malassezia inhibitor | |
| CN115708823B (en) | Application of ursin in preparation of medicines for preventing and/or treating sepsis lung injury | |
| CN103284989A (en) | Application of tanshinol derivatives in preparation of drug for preventing cardiovascular-related diseases | |
| CN108653277A (en) | Application of the kawain derivative in preparing anti-candida albicans drug | |
| CN108743575A (en) | Application of the butyl p-hydroxybenzoate in preparing anti-candida albicans drug | |
| CN103751160A (en) | Application of 2-[3, 5-dihydroxy-2-(1-acyl) phenyl] acetate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170111 |
|
| RJ01 | Rejection of invention patent application after publication |